Literature DB >> 16010499

Prognostic value of MIB-1, E-cadherin, and CD44 in pediatric chordomas.

Aly G Saad1, Margaret H Collins.   

Abstract

The prognosis of pediatric chordomas is difficult to predict based on histology. The objective of this study was to assess the expression of a proliferation marker and adhesion molecules in pediatric chordomas and relate the expressions to outcome. In 8 pediatric chordomas, we calculated the MIB-1 labeling index (LI) by counting the number of MIB-1-positive tumor cells in 100 tumor cells. The grade of expression of E-cadherin and CD44 was calculated by estimating the percentage of tumor cells expressing these markers. MIB-1 LI correlated with tumor recurrence (P = 0.007) and low survival rate (P = 0.007). The expression of E-cadherin correlated with disease-free survival (P = 0.009), tumor recurrence (P > 0.0007), and low survival rate (P > 0.0007). CD44 expression did not correlate with recurrence (P = 0.056) or survival rate (P = 0.056). Our results suggest that MIB-1 LI and expression of E-cadherin are helpful to predict outcome in pediatric chordomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16010499     DOI: 10.1007/s10024-005-1127-z

Source DB:  PubMed          Journal:  Pediatr Dev Pathol        ISSN: 1093-5266


  4 in total

1.  In chordoma, metastasis, recurrences, Ki-67 index, and a matrix-poor phenotype are associated with patients' shorter overall survival.

Authors:  Adrian von Witzleben; Lukas T Goerttler; Jochen Lennerz; Stephanie Weissinger; Marko Kornmann; Regine Mayer-Steinacker; Alexandra von Baer; Markus Schultheiss; Peter Möller; Thomas F E Barth
Journal:  Eur Spine J       Date:  2015-09-23       Impact factor: 3.134

2.  Reversion-inducing cysteine-rich protein with kazal motifs and matrix metalloproteinase-9 are prognostic markers in skull base chordomas.

Authors:  Nunung Nur Rahmah; Keiichi Sakai; Jun Nakayama; Kazuhiro Hongo
Journal:  Neurosurg Rev       Date:  2009-10-28       Impact factor: 3.042

3.  Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study.

Authors:  Mauro Longoni; Francesca Orzan; Michela Stroppi; Nicola Boari; Pietro Mortini; Paola Riva
Journal:  Neuro Oncol       Date:  2007-12-19       Impact factor: 12.300

4.  Prognostic molecular biomarkers in chordomas: A systematic review and identification of clinically usable biomarker panels.

Authors:  Franco Rubino; Christopher Alvarez-Breckenridge; Kadir Akdemir; Anthony P Conley; Andrew J Bishop; Wei-Lien Wang; Alexander J Lazar; Laurence D Rhines; Franco DeMonte; Shaan M Raza
Journal:  Front Oncol       Date:  2022-09-29       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.